MDT$87.16

Medtronic shows steady, mid-single-digit top-line expansion, with revenue rising from $31.2bn to $36.4bn over the period and TTM essentially flat versus FY2026, suggesting growth is moderating after a stronger year. Gross margin has been broadly stable to slightly improving, while operating margin has held near the high-teens/low-20s range, indicating decent conversion of sales into operating profit despite higher SG&A and R&D. Net income has generally trended upward, though FY2023 dipped and FY2024 benefited from improved tax and other income; FY2025–TTM looks more normalized. Versus typical large-cap medical device peers, performance is solid but not exceptional. Key flags are rising operating expenses and the jump in TTM tax rate, which could pressure earnings quality if sustained.

Medtronic’s balance sheet shows solid liquidity and a generally stable capital structure. Total current assets increased to $24.8 billion against current liabilities of $11.7 billion, leaving working capital of $13.1 billion, which indicates ample short-term coverage. Cash and short-term investments are strong at $9.2 billion, supported by a sizable receivables base and inventory near $6.0 billion. Total assets rose to $93.0 billion while total liabilities were $43.0 billion, keeping equity comfortably positive at $49.5 billion. Long-term debt of $26.1 billion is meaningful but still manageable relative to assets and equity. The main caution is the negative tangible book value, reflecting heavy intangibles and goodwill, though retained earnings continue to grow and equity recovered after a FY2025 dip.

Medtronic shows steady cash generation, with operating cash flow rising from $6.0B in FY2023 to $7.3B in FY2026, and the TTM matching FY2026 at $7.3B. Free cash flow also improved from $4.6B to $5.4B despite higher capital spending, which suggests reinvestment is being handled in a controlled way. The gap between net income and CFO is not alarming because depreciation and amortization are large, though working capital has been a drag and the negative change widened to $1.4B. Capital returns remain consistent through dividends and buybacks, while debt activity is active but not excessive. Overall, cash flow quality is solid, with manageable volatility and healthy FCF coverage.

Medtronic shows solid overall quality, with liquidity remaining comfortably above short-term needs and improving again in the latest period after a mid-cycle dip. Debt-to-equity has risen modestly from FY2023 to FY2025 before easing slightly in TTM, suggesting leverage is higher than earlier but still manageable. Asset turnover has steadily improved, indicating better use of the asset base. Profitability is the strongest area: gross margin has been remarkably stable, operating and pre-tax margins have held up well, and ROA and ROE have both trended upward over the period, with TTM still near recent highs. The data points to a stable, steadily efficient operating profile.

Medtronic’s trajectory shows a clear shift from modest revenue growth and weaker EPS in the early period to stronger forward momentum. Revenue expanded from 31.23B USD to 33.54B USD, then analysts model a step-up to 36.36B USD and 38.83B USD, indicating re-acceleration rather than a flat compounding profile. EPS was choppy historically, but forecast growth of 7.58% and 7.79% points to improving earnings stability, though earnings growth lags the stronger revenue step-up in FY2026, suggesting some margin pressure before normalizing. Sentiment is constructive: consensus is Buy, targets cluster around 98.44 USD with a 78 to 121 USD range, and coverage from 25 analysts supports a reasonably confident view. The recommendation mix has stayed broadly stable with a modestly favorable tilt.